Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer

Authors

Matthew J. Ellis, Washington University School of Medicine in St. Louis
et al.

Journal

The New England Journal of Medicine

Publication Date

2019

Volume

380

Issue

25

Inclusive Pages

2395-2405

Document Type

Open Access Publication

DOI

10.1056/NEJMoa1904819

Rights and Permissions

Sparano, J. A., Gray, R. J., Ravdin, P. M., Makower, D. F., Pritchard, K. I., Albain, K. S., . . . Sledge, G. W. (2019). Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. New England Journal of Medicine, 380(25), 2395-2405. doi:10.1056/NEJMoa1904819 Copyright © 2019 Massachusetts Medical Society. All rights reserved.

Recommended Citation

Ellis, Matthew J. and al., et, "Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer." The New England Journal of Medicine. 380, 25. 2395-2405. (2019).
https://digitalcommons.wustl.edu/open_access_pubs/7970